Fig. 5: Assessment of PRRSV-neutralising antibody responses post-vaccination and -challenge. | npj Vaccines

Fig. 5: Assessment of PRRSV-neutralising antibody responses post-vaccination and -challenge.

From: A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate

Fig. 5

Serum samples from day 38 and 56 (3 and 21 DPC) were assessed for their ability to neutralise MARC-145 cell infection by vaccine viruses and BALC infection by challenge viruses. Neutralisation of EU-PRRSV-Con by study 1 (A), 2 (B) and 3 (C) sera; benchmark MLV by study 1 (D), 2 (E) and 3 (F) sera; 215-06 by study 1 sera (G); 21301-19 by study 2 sera (H); and SU1-Bel by study 3 sera (I) are shown with datapoints representing individual pig sera, and bars represent median values for each treatment group. Significances (p < 0.05) are described by letters where a: significant difference from EU-PRRSV-Con/challenged; b: significant difference from benchmark MLV/challenged; c: significant difference from unvaccinated/challenged; d: significant difference from EU-PRRSV-Con/no challenge; e: significant difference from benchmark MLV/no challenge.

Back to article page